Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 5/20 | 0.45 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767502 | 0.87 | ALDH1A1 (0.43) | SMN1; SMN2NPC1RAB9AKDM4EMAPT | |
| SCHEMBL1528138 | 0.76 | KDM4E (0.54) | SMN1; SMN2NPC1RAB9AALOX15KDM4E | |
| SCHEMBL809829 | 0.75 | RAB9A (1.00) | SMN1; SMN2NPC1RAB9AALOX15KDM4E | |
| SCHEMBL8050601 | 0.74 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AALOX15MAPT | |
| Hydrogen Sulfide SCHEMBL11606123 | 0.74 | RAB9A (0.97) | SMN1; SMN2NPC1RAB9AALOX15KDM4E | |
| SCHEMBL3284981 | 0.73 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9AALOX15KDM4E | |
| SCHEMBL30681219 | 0.71 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AALOX15MAPT | |
| SCHEMBL21114860 | 0.71 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9AALOX15MAPT | |
| SCHEMBL8057526 | 0.71 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9AALOX15MAPT | |
| SCHEMBL3830977 | 0.69 | PTK2 (0.54) | SMN1; SMN2PTK2KDM4EMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148232-B2 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1380587-B1 | Oxazolo, thiazolo and selenazolo [4,5-c]naphthyridine-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20050026943-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2005-02-03 | — | — | US | disclosed |
| US-6809203-B2 | IMMUNOMODULATORS; INDUCING CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON-ALPHA AND/OR TUMOR NECROSIS FACTOR-ALPHA | 3M INNOVATIVE PROPERTIES COMPANY | 2004-10-26 | — | — | US | disclosed |
| US-20040122041-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-6703402-B2 | IMMUNOMODULATORS; INDUCERS OF CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON AND/OR TUMOR NECROSIS FACTOR; ANTITUMOR AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-03-09 | — | — | US | disclosed |
| EP-1380587-A2 | Oxazolo, thiazolo and selenazolo (4,5-c)-quinoline-4-amines and analogs thereof | 3M Innovative Properties Company (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6677334-B2 | IMMUNOMODULATORS, INDUCE CYTOKINE BIOSYNTHESIS, AND ANTINEOPLASTIC AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030195224-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-6627640-B2 | Viricides; anticancer agents | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-30 | — | — | US | disclosed |
| EP-1100802-B1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLINE-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES CO (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030065006-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| US-20030064968-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-03 | — | — | US | disclosed |
| US-20030045545-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2003-03-06 | — | — | US | disclosed |
| US-6440992-B1 | ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; USEFUL FOR THERAPY OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2002-08-27 | — | — | US | disclosed |
| US-20020072528-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2002-06-13 | — | — | US | disclosed |
| US-6323200-B1 | THE COMPOUNDS ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT THE T-HELPER-TYPE 2 IMMUNE RESPONSE. | 3M INNOVATIVE PROPERTIES COMPANY | 2001-11-27 | — | — | US | disclosed |
| EP-1100802-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6110929-A | IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-08-29 | — | — | US | disclosed |
| WO-2000006577-A1 | OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064968-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | SMN1; SMN2 3998/4885NPC1 4349/4885RAB9A 3868/4885 |
| US-20020072528-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | SMN1; SMN2 3998/4885NPC1 4349/4885RAB9A 3868/4885 |
| US-20030065006-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | SMN1; SMN2 3998/4885NPC1 4349/4885RAB9A 3868/4885 |
| US-20030195224-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof | IFNG, THPO, IL2 | SMN1; SMN2 3998/4885NPC1 4349/4885RAB9A 3868/4885 |
| US-20050026943-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, IL2, IRF3 | SMN1; SMN2 3080/4885NPC1 4438/4885RAB9A 3701/4885 |
| US-20040122041-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | SMN1; SMN2 3998/4885NPC1 4349/4885RAB9A 3868/4885 |
| US-20030045545-A1 | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof | IFNG, THPO, IL2 | SMN1; SMN2 3998/4885NPC1 4349/4885RAB9A 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.